CODEN [USA]: IAJPBB ISSN: 2349-7750

INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES

http://doi.org/10.5281/zenodo.2013808

Available online at: http://www.iajps.com Review Article

OVERVIEW OF LIVER FAILURE, COMPLICATIONS AND THERAPEUTIC APPROACHES

Mohammed Ahmed A. Alamari[1], Saleh Mohammad S. Alqahtani[1], Abdulelah Mohammed Ahmed Abusabah[1], .Hamad Mohammed Ahmed Abusebah[1], Mohamed Ayed Al sehmah[1], Mohammed Awadh S Alqahtani[1], Ali Ahmed Bajafar[1] Ibrahim Hassan M. Almousaedi[1], Ali Salem S Al Mannaa[1], Ahlam Falah M. Alotaibi[2], Weaam Ahmed H Al-Manea[3], Enas Abdulkarim Alkhoutani[4]

[1]King Khalid University
[2]King Saud bin Abdulaziz University for Health Sciences,
[3]King Saud bin Abdulaziz University for Health Sciences
[4]Umm Alqura University

Abstract:

Cerebral oedema, infection and multi-organ failure are the most common causes of death in ALF. Chronic liver disease (CLD) results in significant morbidity and death, mainly due to issues [hepatic encephalopathy, ascites, hepatorenal syndrome (HRS) and esophageal variceal hemorrhage (EVH)]. Management, for that reason, must intend to stop these complications to permit the liver to regrow or, if this is not likely, to allow adequate time to identify an appropriate organ for transplant. Computerized search was performed using following databases; CENTRAL, PUBMED, MEDLINE, and EMBASE. for all published studies concerning Lichen Planus up to 2018. Using the term ''liver failure. Death of ALF is still unacceptably high. Although considerable progress has actually been made in the understanding of the pathophysiology of ALF, clinical trials are limited. Liver transplantation is the best treatment for a high proportion of ALF patients. In order to maximize the results of liver transplant, approaches of connecting are under growth. Modest hypothermia is a major enhancement to the arsenal, enabling patients with serious, uncontrolled intracranial high blood pressure to be linked successfully to transplant.

Corresponding author:
Mohammed Ahmed A. Alamari,
King Khalid University

QR code

Please cite this article in press Mohammed Ahmed A. Alamari et al., ***Overview of Liver Failure, Complications and Therapeutic Approaches.,*** *Indo Am. J. P. Sci, 2018; 05(12).*

INTRODUCTION:

Acute liver failure (ALF) is a disorder in which acute loss of metabolic and synthetic liver function brings about hepatic encephalopathy and multiorgan failing within a short time in patients with no previous background of liver illness. The syndrome is categorized into hyperacute, acute and subacute liver failure according to the onset of hepatic encephalopathy within 7 days, 8-- 28 days, and greater than 28 days, specifically [1]. The aetiology varies between countries. Worldwide, infections (hepatitis A, B and E) are the most prevalent source of ALF, whereas in western Europe and the USA, acetaminophen poisoning is the leading cause, being accountable for 20% of instances [1]. Mortality rates in patients with ALF vary considerably in various research studies, varying from 10% to 90%, but still remain unacceptably high [2].

Chronic liver disease (CLD) is the gradual destruction of liver parenchyma gradually as a result of any chronic injury to the liver. Numerous various pathophysiological mechanisms lead to a final prevalent path of functioning hepatic tissue being changed by scar tissue, or fibrosis, bring about damaged hepatic function [3]. For many years, the clinical treatment of CLD has been centered on signs and symptom control and the prevention of problems. Although necessarily cirrhosis cannot be dealt with totally, it is possible to reduce, stop, and even reverse progression of fibrosis [3]. Nevertheless, when decompensation becomes refractory to clinical therapy the only tested treatment for end-stage liver disorder is liver transplantation regardless of initial etiology [3].

Cerebral oedema, infection and multiorgan failure are the most common causes of death in ALF. Chronic liver disease (CLD) results in significant morbidity and death, mainly due to issues [hepatic encephalopathy, ascites, hepatorenal syndrome (HRS) and esophageal variceal hemorrhage (EVH)]. Management, for that reason, must intend to stop these complications to permit the liver to regrow or, if this is not likely, to allow adequate time to identify an appropriate organ for transplant.

METHODOLOGY:

Computerized search was performed using following databases; CENTRAL, PUBMED, MEDLINE, and EMBASE. for all published studies concerning Lichen Planus up to 2018. using the term ‘‘liver failure, and searched PubMed, using the Medical Subject Heading (MeSH) term ‘‘liver failure” and free-text words such “management”, complications” and “treatment”. we restricted our search to only English published articles with human subjects.

DISCUSSION:

- **Chronic liver disease complications and Management approaches**

The occurrence of chronic liver disease (CLD) remains to ascend, particularly with the epidemic of excessive weight and viral hepatitis. Chronic injury to the liver, despite the reason, causes a wounding reaction that result in fibrosis and ultimately scarring and replacing of typical liver architecture by regenerative nodules. This process, along with the overflow of endogenous vasoconstrictors like endothelins and underproduction of vasodilators like nitric oxide, results in a rise in intrahepatic resistance and portal high blood pressure. Clinically considerable difficulties of CLD as a result of portal high blood pressure appear to be restricted to situations in which the hepatic venous pressure gradient (HVPG) is elevated to above 10 mmHg [4].

Hepatic encephalopathy

Hepatic encephalopathy is defined as a complex neuropsychiatric syndrome marked by personality changes, intellectual problems, and a changed degree of consciousness. Hepatic encephalopathy is connected with hepatocyte loss and disorder, and portosystemic shunting, which enable nitrogenous compounds stemmed from the gut to detrimentally impact brain function. It is a frequent and traumatic complication, establishing in 30% to 45% of patients with decompensated cirrhosis [5].

Hepatic encephalopathy arising from cirrhosis is identified according to the extent of clinical indications, the time course, and the existence of speeding up elements. The West Haven Criteria rank the clinical severity of HE from grade I to IV, as outlined in Table 1 [6]. Grade I or marginal HE explains patients without medical symptoms however refined results on neurophysiologic and neuropsychometric testing, which might have implications for fitness to drive. Overt HE (grades II and III) is made use of to describe patients who demonstrate gross disorientation or asterixis, and obvious HE can proceed to grade IV, which is coma. Hepatic encephalopathy can be more subcategorized as episodic, frequent, or persistent [5].

Table 1. West Haven Criteria for altered mental state in hepatic encephalopathy [6].

Grade I	• Trivial lack of awareness • Euphoria or anxiety • Shortened attention span • Impairment of addition or subtraction • Altered sleep rhythm
Grade II	• Lethargy or apathy • Disorientation for time • Obvious personality change • Inappropriate behaviour • Dyspraxia • Asterixis
Grade III	• Somnolence or semistupor • Responsive to stimuli • Confused • Gross disorientation • Bizarre behaviour
Grade IV	• Coma

Treatment goals for hepatic encephalopathy include stipulation of helpful care, recognition and removal of precipitating elements, reduction in the nitrogenous load from the gut, and optimization of long-term therapy [8]. Treatment should be directed towards developing psychological standing by means of bowel cleansing with lactulose by mouth or with enemas Table 2 [7-10]. One randomized test demonstrated that diets with normal protein content can be followed safely throughout episodic hepatic encephalopathy brought on by cirrhosis, and that protein constraint has no advantageous result throughout such episodes [8]. In patients that are refractory to lactulose alone, neomycin can be added [9].

Boosts in the proportion of plasma aromatic amino acids to branched-chain amino acids as a consequence of hepatic insufficiency additionally might contribute to encephalopathy. One meta-analysis suggested that psychological recovery was constantly a lot quicker in patients whose therapy consisted of a branched-chain amino acid mixture; 3 researches identified lower mortality rates in patients who got this therapy, and 2 others recommended that the treatment grew death [10]. Another physiologic theory of hepatic encephalopathy is that endogenous benzodiazepines might bind to γ-aminobutyric acid receptors and apply neuroinhibitory impacts. Use of the benzodiazepine receptor antagonist f lumazenil (Romazicon) may enhance psychological condition transiently, whereas bromocriptine (Parlodel) may boost extrapyramidal symptoms. No official referral for the regular use of any of these representatives has been recommended.

Table 2. Treatment of Complications of Cirrhosis [7-10].

COMPLICATION	***TREATMENT***	***DOSAGE***
Ascites	Sodium restriction	Maximum 2,000 mg per day
	Spironolactone (Aldactone)	Start 100 mg orally per day; maximum 400 mg orally per day
	Furosemide (Lasix)	Start 40 mg orally per day; maximum 160 mg orally per day
	Albumin	8 to 10 g IV per liter of fluid (if greater than 5 L) removed for paracenteses

COMPLICATION	*TREATMENT*	*DOSAGE*
	Fluid restriction	Recommended if serum sodium is less than 120 to 125 mEq per L (120 to 125 mmol per L)
Spontaneous bacterial peritonitis	Cefotaxime (Claforan)	2 g IV every eight hours
	Albumin	1.5 g per kg IV within six hours of detection and 1 g per kg IV on day 3
	Norfloxacin (Noroxin)	400 mg orally two times per day for treatment
		400 mg orally two times per day for seven days with gastrointestinal hemorrhage
		400 mg orally per day for prophylaxis
	Trimethoprim/sulfamethoxazole	1 single-strength tablet orally per day for prophylaxis
	(Bactrim, Septra)	1 single-strength tablet orally two times per day for seven days with gastrointestinal hemorrhage
Hepatic encephalopathy	Lactulose	30 to 45 mL syrup orally titrated up to three or four times per day or 300 mL retention enema until two to four bowel movements per day and mental status improvement
	Neomycin	4 to 12 g orally per day divided every six to eight hours; can be added to lactulose in patients who are refractory to lactulose alone
Portal hypertension and variceal bleeding	Propranolol (Inderal)	40 to 80 mg orally two times per day
	Isosorbide mononitrate (Ismo)	20 mg orally two times per day
Hepatorenal syndrome	Midodrine (ProAmatine) and octreotide (Sandostatin)	Dosed orally (midodrine) and IV (octreotide) to obtain a stable increase of at least 15 mm Hg mean arterial pressure
	Dopamine	2 to 4 mcg per kg per minute IV (nonpressor dosing to produce renal vasodilatation)

IV = intravenously; PMNL = polymorphonuclear leukocyte.

Spontaneous bacterial peritonitis

Spontaneous bacterial peritonitis is specified as an ascitic liquid infection with a polymorphonuclear cell count of 250 cell/mm3 or greater and an ascitic liquid culture favorable for microorganisms, in the lack of an operatively treatable source. Spontaneous microbial peritonitis is the most usual and serious infection in patients with cirrhosis: up to 30% of patients with cirrhosis create SBP, with a mortality rate varying in between 30% and 50% [11].

Patients with ascitic fluid polymorphonuclear leukocyte (PMNL) counts of 250 cells per mm3 or higher ought to obtain empiric antibiotic therapy

(e.g., cefotaxime [Claforan] 2 g intravenously every eight hours) and albumin (1.5 g per kg body weight within 6 hrs of discovery and 1 g per kg on day 3) to avoid spontaneous bacterial peritonitis Table 2. Oral ofloxacin (Floxin; 400 mg twice daily) is an alternate to intravenous medicines in patients without throwing up, shock, severe hepatic encephalopathy, or a creatinine degree greater than 3 mg per dL (265 μmol per L) [7]. Patients with ascitic fluid PMNL counts less than 250 cells per mm3 and signs and symptoms of infection ought to obtain empiric antibiotic therapy while awaiting culture results [7]. Patients that make it through an episode of spontaneous microbial peritonitis should get lasting prophylaxis with norfloxacin (Noroxin) or trimethoprim/sulfamethoxazole (Bactrim, Septra). Patients with gastrointestinal hemorrhage and cirrhosis should receive norfloxacin or trimethoprim/sulfamethoxazole twice daily for seven days (the medication is then ceased) [7].

Esophageal Varices

Esophageal varices, a direct repercussion of grown portal stress, are a typical issue of cirrhosis, and their presence associates with the seriousness of liver illness. Approximately 50% of patients with cirrhosis establish esophageal varices, and of this one-third will establish a variceal bleed [12]. With any episode of active blood loss, there is a 30% possibility of mortality and a 70% risk of hemorrhage reoccurrence within 1 year [12].

Primary treatment consists of indefinite use of non-selective β-blockers such as nadolol or propranolol, with the objective of lowering the standard relaxing heart rate by 25%, with a heart rate no lower than 55 beats/min [12]. Nadolol has the advantage of being provided just daily, typically beginning at 40 mg once a day; nonetheless, it is renally eliminated and its starting dose might require alteration if the patient has any type of kidney insufficiency. Propranolol is usually begun at 20 mg twice daily. If a patient cannot tolerate β-blockers or there are contraindications to their use, such as a previous episode of SBP or in cases of disagreement, prophylactic esophageal variceal ligation can be offered.

Hepatorenal syndrome

Hepatorenal syndrome (HRS) is an exceptionally bothersome complication of CLD, and (type 1) HRS portends a poor prognosis. A meta-analysis of randomized controlled tests (RCTs) assessed the efficiency of terlipressin with albumin in kind 1 HRS [13]. In the last analysis of 4 tests, an overall of 223 patients had HRS reversal 46% of the time when obtaining terlipressin compared with 11.6% in controls, with a risk ratio for reversal of 3.66 (95% CI 2.15- 6.23, P < 0.00001). The rate of HRS recurrence was low (8% for terlipressin versus 12.5% in controls). Ischemia-related side-effects were reported in 10.3% in the terlipressin group, which was more common than in the control group [13].

Hemodialysis frequently is made use of to control azotemia in hepatorenal syndrome and to deal with electrolyte inequalities. Nonsteroidal anti-inflammatory drugs and possibly nephrotoxic medications should be avoided. One regulated trial demonstrated a significant renovation in kidney plasma f reduced, glomerular filtering rate, and urinary sodium excretion in patients with type 1 hepatorenal syndrome after 20 days of therapy with oral midodrine (ProAmatine) and parenteral octreotide compared to making use of nonpressor dose dopamine Table 2 [7-10]. These treatments additionally appear to increase survival rates and might serve as a bridge to liver transplant. In the future, endothelins, adenosine antagonists, long-acting vasoconstrictors, and antileukotriene antagonists might play a role in stopping and treating hepatorenal disorder [14].

Liver Transplantation

When basic clinical and procedural therapy has stopped working to regulate the difficulties of cirrhosis, liver transplant ought to be considered. Unneeded surgeries should be prevented and dangers versus benefits considered before any surgical procedure is carried out in patients with cirrhosis. Considering that the first successful liver transplant in 1967, there has been an expanding variation in between the variety of possible candidates and the variety of donors. This disparity is attributed to a sixfold rise in patients on the transplant waiting list from 1991 to 2001 and a much slower rate of raise in the donor pool. A total amount of 6,169 liver transplants were executed in the United States in 2004; the present waiting list includes regarding 17,900 candidates [15]. Survival rates have actually improved noticeably since the very first transplant as a result of considerable enhancements in immunosuppression and clinical and surgery care experience. For liver transplants executed in the United States from 1996 to 2001, survival rates after one, three, and 5 years were 87.6, 79.9, and 74.5 percent, respectively [15].

The Clinical Practice Committee of the American Society of Transplantation recommends patients ought to be referred early to a transplant subspecialist

to enable time for the patient, family, referring doctor, and transplant center to meet and identify any type of potential troubles [15]. Transplant care is best offered by a team of healthcare professionals including a hepatologist, a surgeon, a psychiatrist, and a social worker. Along with a conventional medical examination, the preliminary assessment of a possible transplant recipient needs to include education highlighting the threats and advantages of body organ transplant, consisting of the potential for poor outcomes (i.e., body organ rejection), and standard post-transplant care.

- **General management of Acute Liver complications**

ALF results in the failure of nearly all organ systems in which infection complicates the course and outcome. A lot of more specific concerns connecting to management that are specifically pertinent to liver failing are gone over listed below.

Cerebral oedema and hepatic encephalopathy

One of the most threatening issue of ALF is the development of cerebral oedema causing hepatic encephalopathy, coma and ultimately to brain herniation and death. The pathophysiology of cerebral oedema in ALF is not fully comprehended. Autoregulation of cerebral blood flow is lost and oxygen extraction and glucose use are impaired. Ammonia metabolic process is deranged resulting in modifications in glutamate uptake and a higher extracellular glutamate concentration which initiates further brain swelling. Furthermore, systemic inflammatory action appears to play an extra function by altering cerebral blood flow and cellular bioenergetics [16].

For optimal therapeutic management, intracranial pressure monitoring is advised, however the threat of problems must be weighed against the possible advantage (1% fatal haemorrhage) [17]. Hostile management of coagulation disruptions, maybe with factor VII, can alleviate these problems [18]. There are different therapeutic techniques offered to target the various pathophysiological ideas reviewed over. Cerebral blood flow can be affected by inducing vasoconstriction by hyperventilation or administration of thiopental sodium, propofol or indomethacin, however none of these techniques enhance prognosis and they bear a substantial threat. Ammonia metabolic process was targeted by lactulose, branched chain amino acids, nonabsorbable antibiotics or L-ornithine-L-aspartate however none of these medicines was checked in randomized trials in ALF. To minimize brain oedema, mannitol has been revealed to be the best treatment choice. Thinking about the negative influence of systemic swelling, steroids were checked but discovered to be inefficient in preventing cerebral oedema and enhancing survival. Similarly, hepatectomy was considered to reduce the deleterious results of unidentified compounds released by the lethal liver, which has been revealed to support cardiovascular and cerebrovascular state [16].

Modest hypothermia is a promising strategy affecting several paths in the pathophysiology of mind oedema. Clinical studies revealed that cooling ALF patients who have irrepressible intracranial high blood pressure to 328C works in lowering intracranial pressure and is risk-free as a bridging technique to liver transplantation [19] (Fig. 1).



Figure 1. Pathophysiological basis for the therapy of increased intracranial pressure [16], [19]

CVVHF, continuous veno-venous haemofiltration; LOLA, L-ornithine-L-aspartate

Adrenal insufficiency

Adrenal insufficiency, as figured out by a pathological brief synacthen examination, was discovered in 62% of patients with ALF [20]. Adrenal insufficiency correlates with seriousness of illness and might contribute to the hemodynamic instability and death. Supraphysiological doses of corticosteroids have actually been revealed to minimize inotrope needs in ALF. Although they did not boost survival, corticosteroids might aid in prolonging the moment to find an appropriate donor [21].

Inflammation and infection

About 60% of all ALF patients were shown to satisfy the requirements of the systemic inflammatory reaction syndrome, whether precipitated by infection [22]. This appears to be implicated in the development of hepatic encephalopathy and provides a poorer diagnosis. Damaged immune function in ALF leads to an increased incidence of bacterial and fungal infections, which is additionally connected with aggravating of hepatic encephalopathy. Prophylactic antibiotics are utilized commonly and have actually been shown to lower infection rates [23]. Considering that every device selects an antibiotic regimen according to the results of microbiological research studies and resistance data, randomized research studies are difficult to perform.

Renal failure

Renal failure happens in more than 50% of patients with ALF, either as a result of an insult that affects liver and kidney (such as acetaminophen) or due to a hyperdynamic state in ALF. For renal support, continual veno-venous haemofiltration is better to haemodialysis as this is associated with much less extreme liquid shifts reducing the danger of aggravating of cerebral oedema [24].

Transplantation

The only treatment of confirmed advantage in ALF is emergency liver transplant, although survival after transplant is still significantly less than in optional liver transplant [25]. Given that scarcity of donor organs limits this option in Europe, the KCC are most widely accepted to pick those patients that are most likely to pass away without transplant. Complementary liver transplantation is a strategy where a decreased size liver graft is placed listed below the patient's liver in the hepatic bed after a portion of the native liver has actually been extracted. A possible benefit is that this treatment may sustain the patient while the native liver restores however provides the possibility of a life without the demand for chronic immunosuppression later on. On top of that, because just a small portion of the donor liver is called for, the continuing to be component can be made use of in a basic organ transplant to raise the variety of available organs [25]. The treatment is technically difficult, nevertheless, and has actually not been appropriately evaluated in regulated medical tests [25].

CONCLUSION:

Death of ALF is still unacceptably high. Although considerable progress has actually been made in the understanding of the pathophysiology of ALF, clinical trials are limited. Liver transplantation is the best treatment for a high proportion of ALF patients. In order to maximize the results of liver transplant, approaches of connecting are under growth. Modest hypothermia is a major enhancement to the arsenal, enabling patients with serious, uncontrolled intracranial high blood pressure to be linked successfully to transplant.

The problems of end phase liver disease prevail and they can either develop alone or all at once. Cirrhosis is the final common end point in patients with progressive liver illness of various causes. Other typical difficulties of end-stage liver disease include ascites, hepatic encephalopathy, spontaneous microbial peritonitis, and esophageal varices.

When taking into consideration management of any problem, the possible results of the therapies ought to be thought about against the risk of establishing or worsening various other problems. It is prudent to have mindful discussions ahead of any kind of situation, taking into consideration each difficulty and the potential for rapid decline and considering a patient's goals of care, prognosis, total sign problem, and the burden-to-benefit proportion of available therapy options.

REFERENCES:

1. Schiodt FV, Atillasoy E, Shakil AO, et al. Etiology and outcome for 295 patients with acute liver failure in the United States. Liver Transpl Surg 1999; 5:29–34.
2. O'Grady JG. Acute liver failure. Postgrad Med J 2005; 81:148–154.
3. Pellicoro A, Ramachandran P, Iredale JP, Fallowfield JA. Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nature reviews. 2014;14(3):181–94.
4. Sharma BC, Sharma P, Agrawal A, Sarin SK. Secondary prophylaxis of hepatic

encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. Gastroenterology 2009; 137:885–891.

5. Poordad FF. Review article: the burden of hepatic encephalopathy. Aliment Pharmacol Ther. 2007;25(Suppl 1):3–9.

6. Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60(2):715–35.

7. Runyon BA. and the Practice Guidelines Committee, American Association for the Study of Liver Diseases Management of adult patients with ascites due to cirrhosis. *Hepatology*. 2004;39:841–56.

8. Fitz JG. Hepatic encephalopathy, hepatopulmonary syndromes, hepatorenal syndrome, coagulopathy, and endocrine complications of liver disease. In: Feldman M, Friedman LS, Sleisenger MH, eds. Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. 7th ed. Philadelphia, Pa.: Saunders, 2002:1543–54.

9. Strauss E, Tramote R, Silva EP, Caly WR, Honain NZ, Maffei RA, et al. Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy. Hepatogastroenterology. 1992;39:542–5.

10. Jalan R, Hayes PC. UK guidelines on the management of variceal haemorrhage in cirrhotic patients. British Society of Gastroenterology. *Gut*. 2000;46(suppl 3–4):III1–III15.

11. Gines P, Rimola A, Planas R, Vargas V, Marco F, Almela M, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology. 1990;12(4 Pt 1):716–24.

12. O'Brien J, Triantos C, Burroughs AK. Management of varices in patients with cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10(7):402–12.

13. Sagi SV, Mittal S, Kasturi KS, Sood GK. Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials. J Gastroenterol Hepatol 2010; 25:880–885.

14. Moller S, Henriksen JH. Review article: pathogenesis and pathophysiology of hepatorenal syndrome—is there scope for prevention?. *Aliment Pharmacol Ther*. 2004;20(suppl 3):31–41.

15. United Network for Organ Sharing. Data. Accessed May 12, 2006, at: http://www.unos.org/data/.

16. Jalan R. Pathophysiological basis of therapy of raised intracranial pressure in acute liver failure. Neurochem Int 2005; 47:78–83.

17. Blei AT, Olafsson S, Webster S, Levy R. Complications of intracranial pressure monitoring in fulminant hepatic failure. Lancet 1993; 341:157–158.

18. Shami VM, Caldwell SH, Hespenheide EE, et al. Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy. Liver Transpl 2003; 9:138–143.

19. Jalan R, Damink SW, Deutz NE, et al. Moderate hypothermia for uncontrolled intracranial hypertension in acute liver failure. Lancet 1999; 354:1164–1168.

20. Harry R, Auzinger G, Wendon J. The clinical importance of adrenal insufficiency in acute hepatic dysfunction. Hepatology 2002; 36:395–402.

21. Harry R, Auzinger G, Wendon J. The effects of supraphysiological doses of corticosteroids in hypotensive liver failure. Liver Int 2003; 23:71–77.

22. Schmidt LE, Larsen FS. Prognostic implications of hyperlactatemia, multiple organ failure, and systemic inflammatory response syndrome in patients with acetaminophen-induced acute liver failure. Crit Care Med 2006; 34:337– 343.

23. Rolando N, Gimson A, Wade J, et al. Prospective controlled trial of selective parenteral and enteral antimicrobial regimen in fulminant liver failure. Hepatology 1993; 17:196–201.

24. Davenport A. Haemofiltration in patients with fulminant hepatic failure. Lancet 1991; 338:1604.

25. Adam R, Cailliez V, Majno P, et al. Normalised intrinsic mortality risk in liver transplantation: European Liver Transplant Registry study. Lancet 2000; 356:621–627.